Evidence map›Paper›PMID 25644007›Full record

ArticleInfection and immunity2015

Dendritic cell-based immunization ameliorates pulmonary infection with highly virulent Cryptococcus gattii.

Keigo Ueno, Yuki Kinjo, Yoichiro Okubo, Kyoko Aki, Makoto Urai, Yukihiro Kaneko, Kiminori Shimizu, Dan-Ni Wang, Akiko Okawara, Takuya Nara and 8 more

Open access · bronzeAbstract read
In one paragraph

Article in Infection and immunity, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
3.3field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 35 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Immune evasion byFrontiers in immunology · 2024
    Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Interactions of Cryptococcus with Dendritic Cells.Journal of fungi (Basel, Switzerland) · 2018
    Review
  13. Article
  14. Dendritic Cells Primed withFrontiers in microbiology · 2017
    Article
  15. Review
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 7 institutions in 1 country.

Keigo UenoDepartment of Chemotherapy and Mycoses, National Institute of Infectious Diseases, Tokyo, Japan.
Yuki KinjoDepartment of Chemotherapy and Mycoses, National Institute of Infectious Diseases, Tokyo, Japan ykinjo@niid.go.jp.
Yoichiro OkuboDepartment of Surgical Pathology, Toho University School of Medicine, Tokyo, Japan.
Kyoko AkiDepartment of Surgical Pathology, Toho University School of Medicine, Tokyo, Japan.
Makoto UraiDepartment of Chemotherapy and Mycoses, National Institute of Infectious Diseases, Tokyo, Japan.
Yukihiro KanekoDepartment of Chemotherapy and Mycoses, National Institute of Infectious Diseases, Tokyo, Japan Department of Bacteriology, Graduate School of Medicine, Osaka City University, Osaka, Japan.
Kiminori ShimizuDivision of Molecular Biology, Medical Mycology Research Center, Chiba University, Chiba, Japan.
Dan-Ni WangDivision of Clinical Research, Medical Mycology Research Center, Chiba University, Chiba, Japan.
Akiko OkawaraDepartment of Chemotherapy and Mycoses, National Institute of Infectious Diseases, Tokyo, Japan.
Takuya NaraDepartment of Chemotherapy and Mycoses, National Institute of Infectious Diseases, Tokyo, Japan.
Kayo OhkouchiDepartment of Chemotherapy and Mycoses, National Institute of Infectious Diseases, Tokyo, Japan.
Yuki MizuguchiDepartment of Chemotherapy and Mycoses, National Institute of Infectious Diseases, Tokyo, Japan.
Susumu KawamotoDivision of Molecular Biology, Medical Mycology Research Center, Chiba University, Chiba, Japan.
Katsuhiko KameiDivision of Clinical Research, Medical Mycology Research Center, Chiba University, Chiba, Japan Division of Control and Treatment of Infectious Diseases, Chiba University Hospital, Chiba, Japan.
Hideaki OhnoDepartment of Chemotherapy and Mycoses, National Institute of Infectious Diseases, Tokyo, Japan Department of Infectious Diseases and Infection Control, Saitama Medical Center, Saitama Medical University, Saitama, Japan.
Yoshihito NikiDivision of Clinical Infectious Diseases, Department of Internal Medicine, Showa University School of Medicine, Tokyo, Japan.
Kazutoshi ShibuyaDepartment of Surgical Pathology, Toho University School of Medicine, Tokyo, Japan.
Yoshitsugu MiyazakiDepartment of Chemotherapy and Mycoses, National Institute of Infectious Diseases, Tokyo, Japan.
National Institute of Infectious Diseases · JPToho University · JPChiba University · JPChiba University Hospital · JPOsaka City University · JPSaitama Medical University · JPShowa University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cryptococcosis due to a highly virulent fungus, Cryptococcus gattii, emerged as an infectious disease on Vancouver Island in Canada and surrounding areas in 1999, causing deaths among immunocompetent individuals. Previous studies indicated that C. gattii strain R265 isolated from the Canadian outbreak had immune avoidance or immune suppression capabilities. However, protective immunity against C. gattii has not been identified. In this study, we used a gain-of-function approach to investigate the protective immunity against C. gattii infection using a dendritic cell (DC)-based vaccine. Bone marrow-derived dendritic cells (BMDCs) efficiently engulfed acapsular C. gattii (Δcap60 strain), which resulted in their expression of costimulatory molecules and inflammatory cytokines. This was not observed for BMDCs that were cultured with encapsulated strains. When Δcap60 strain-pulsed BMDCs were transferred to mice prior to intratracheal R265 infection, significant amelioration of pathology, fungal burden, and the survival rate resulted compared with those in controls. Multinucleated giant cells (MGCs) that engulfed fungal cells were significantly increased in the lungs of immunized mice. Interleukin 17A (IL-17A)-, gamma interferon (IFN-γ)-, and tumor necrosis factor alpha (TNF-α)-producing lymphocytes were significantly increased in the spleens and lungs of immunized mice. The protective effect of this DC vaccine was significantly reduced in IFN-γ knockout mice. These results demonstrated that an increase in cytokine-producing lymphocytes and the development of MGCs that engulfed fungal cells were associated with the protection against pulmonary infection with highly virulent C. gattii and suggested that IFN-γ may have been an important mediator for this vaccine-induced protection.

Indexed as

AnimalsBone Marrow CellsCell- and Tissue-Based TherapyCryptococcosisCryptococcus gattiiDendritic CellsFungal CapsulesFungal VaccinesGiant CellsInterferon-gammaInterleukin-17LungLymphocytesMiceMice, Inbred C57BLMice, KnockoutFungal VaccinesIl17a protein, mouseInterferon-gammaInterleukin-17Tumor Necrosis Factor-alpha

Identifiers

PMID25644007
PMCPMC4363414
OpenAlexW2150961044

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.